Skip to main content
Premium Trial:

Request an Annual Quote

Sophia Genetics, Gustave Roussy Expand Partnership With Bidirectional Data Exchange

NEW YORK – Sophia Genetics said Tuesday that it is expanding its six-year-old partnership with Institut Gustave Roussy.

The French cancer institute has updated its laboratory information management system to facilitate bidirectional data exchange with Sophia's flagship Data Driven Medicine (DDM) bioinformatics platform. Sophia said that this will support "more efficient interpretation of data" as Gustave Roussy looks to accelerate diagnostics and development of treatment plans.

Gustave Roussy will now use DDM for all "relevant" samples related to solid tumors, and hematologic and hereditary cancers, according to the Swiss-American bioinformatics firm.

"With the rapidly evolving field of clinical genomics, the challenges of data analysis are now twofold: the ability to meet the production quality requirements … and the ability to innovate with the arrival of new genomic signatures and techniques," Etienne Rouleau, head of the Gustave Roussy genetics unit, said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.